By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AdnaGen 

Ostpassage 7

Langenhagen    D-30853  Germany
Phone: 49-0-511-725950-50 Fax: 49-0-511-725950-40


SEARCH JOBS


Industry
Biotechnology


Collaborations

Gen-Probe Incorporated (Acquired by Hologic)  In January 2005, Gen-Probe signed an agreement with AdnaGen, a private company based in Germany, to license AdnaGen's innovative "immunocapture" technology. The technology may help increase the accuracy of molecular diagnostic tests to detect prostate and other cancers, help determine the aggressiveness of these malignancies, and monitor responses to therapy.





Company News
KellBenx Secures Exclusive Worldwide License With AdnaGen for Commercializing Patented Antibodies 4/6/2011 10:10:30 AM
OncoVista Innovative Therapies, Inc. Sells AdnaGen Subsidiary: Total Sale Price Could Reach $65 Million Over Three Years When Milestones Achieved 11/11/2010 8:13:28 AM
OncoVista Innovative Therapies, Inc. Subsidiary AdnaGen Inks Exclusive Agreement with TATAA Molecular Diagnostics 1/26/2010 9:31:13 AM
LAB21 Limited to Provide AdnaGen's CE-Marked System for the Detection and Analysis of Circulating Tumor Cells (CTCs) in the United Kingdom and Ireland 8/10/2009 1:52:29 PM
OncoVista Innovative Therapies, Inc. Announces the Initiation of Clinical Development of AdnaGen's Breast Cancer Circulating Tumor Cells (CTCs) Diagnostic Technology in Women with High-Risk Locally Advanced Breast Cancer 7/24/2009 8:49:52 AM
AdnaGen and OncoVista Innovative Therapies, Inc., Announce the Issuance in the U.S. of a Key Patent Related to Technology for the Detection and Analysis of Circulating Tumor Cells 3/27/2009 8:43:10 AM
Sysmex Europe GmbH to Distribute Products for the Analysis of Circulating Tumor Cells in Different Tumor Entities Developed by AdnaGen, a Subsidiary of OncoVista Innovative Therapies, Inc. 1/29/2009 10:49:23 AM
OncoVista Innovative Therapies, Inc. Announces Submission of Request for Pre-IDE Determination Meeting with FDA for AdnaGen's AdnaTest Breast Cancer Device for Detection of Circulating Breast Tumor Cells 5/6/2008 8:29:16 AM
OncoVista Innovative Therapies, Inc. Announces Appointment of AdnaGen Chief Executive Officer 4/11/2008 8:33:27 AM
OncoVista Increases Its Share in AdnaGen 12/17/2007 11:44:54 AM
12
//-->